Payment overview · 2025
General Payments
$29.30
1 reported records · 1 companies
Healthcare provider profile · identity verified
Nathan Oldham, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ELDORADO, IL · NPI 1780883843
Verified facts
What the public records show
CMS Open Payments records show Nathan Oldham, M.D. received $29.30 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.30 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $29.30 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 539 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 530 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 94 |
| Furosemide | Furosemide | 459 | 118 |
| Gabapentin | Gabapentin | 390 | 79 |
| Potassium Chloride | Potassium Chloride | 345 | 76 |
| Lisinopril | Lisinopril | 339 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 309 | 73 |
| Omeprazole | Omeprazole | 306 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 68 |
| Losartan Potassium | Losartan Potassium | 282 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 104 |
| Citalopram Hbr | Citalopram Hydrobromide | 267 | 47 |
| Eliquis | Apixaban | 257 | 45 |
| Spironolactone | Spironolactone | 249 | 51 |
| Metformin Hcl | Metformin Hcl | 240 | 50 |
| Metformin Hcl Er | Metformin Hcl | 232 | 48 |
| Montelukast Sodium | Montelukast Sodium | 229 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 53 |
| Prednisone | Prednisone | 218 | 141 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 63 |
| Topiramate | Topiramate | 201 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 32 |
| Carvedilol | Carvedilol | 165 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 162 | 34 |
| Meloxicam | Meloxicam | 160 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 34 |
| Ozempic | Semaglutide | 156 | 21 |
| Famotidine | Famotidine | 152 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 28 |
| Xarelto | Rivaroxaban | 148 | 17 |
| Simvastatin | Simvastatin | 140 | 23 |
| Allopurinol | Allopurinol | 135 | 31 |
| Sertraline Hcl | Sertraline Hcl | 134 | 20 |
| Mounjaro | Tirzepatide | 131 | 25 |
| Glimepiride | Glimepiride | 130 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 22 |
| Januvia | Sitagliptin Phosphate | 127 | 16 |
| Donepezil Hcl | Donepezil Hcl | 123 | 29 |
| Tresiba Flextouch U-200 | Insulin Degludec | 115 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 114 | 27 |
| Memantine Hcl | Memantine Hcl | 99 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 94 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 21 |
| Celecoxib | Celecoxib | 91 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 21 |
| Jardiance | Empagliflozin | 90 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 25 |
| Valsartan | Valsartan | 88 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 87 | 12 |
| Trazodone Hcl | Trazodone Hcl | 87 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 85 | 69 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 22 |
| Atenolol | Atenolol | 82 | 22 |
| Tramadol Hcl | Tramadol Hcl | 82 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 20 |
| Clonidine Hcl | Clonidine Hcl | 70 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 16 |
| Aripiprazole | Aripiprazole | 68 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 14 |
| Trulicity | Dulaglutide | 67 | 11 |
| Gemtesa | Vibegron | 66 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 14 |
| Olanzapine | Olanzapine | 62 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 12 |
| Alprazolam | Alprazolam | 59 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 58 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 15 |
| Cephalexin | Cephalexin | 57 | 41 |
| Alendronate Sodium | Alendronate Sodium | 56 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 54 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 53 | 17 |
| Nifedipine Er | Nifedipine | 52 | suppressed |
| Lorazepam | Lorazepam | 51 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 19 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 16 |
| Mirtazapine | Mirtazapine | 49 | 15 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 11 |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Cilostazol | Cilostazol | 44 | suppressed |
| Movantik | Naloxegol Oxalate | 44 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Klor-Con M20 | Potassium Chloride | 43 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 35 |
| Pregabalin | Pregabalin | 43 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 32 |
| Diazepam | Diazepam | 41 | 21 |
| Clonazepam | Clonazepam | 40 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | 12 |
| Levofloxacin | Levofloxacin | 39 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 14 |
| Cefuroxime | Cefuroxime Axetil | 37 | 33 |
| Fluconazole | Fluconazole | 37 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 25 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Praluent Pen | Alirocumab | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 14 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Nystatin | Nystatin | 27 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Estradiol | Estradiol | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 11 |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Buprenorphine | Buprenorphine | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 12 |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29.30 · 1 records | ABBVIE INC. | VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error